>
Fa   |   Ar   |   En
   Comparison of the Eight Different Treatment Regimens for the Hospitalized Patients with COVID-19:A Retrospective Cohort Study  
   
نویسنده haji aghajan mohammad ,pourheidar elham ,moradi omid ,pourhosseingoli asma ,taherpour niloufar ,barootkoob armineh ,hassanpour rezvan ,agah elmira ,mousavi vahid ,sistanizad mohammad
منبع journal of cellular and molecular anesthesia - 2021 - دوره : 6 - شماره : 4 - صفحه:329 -338
چکیده    Background: coronavirus disease 2019 (covid -19), characterized by a mild to severe respiratory illness, has been affecting the world since late 2019 and leading to an increase in hospitalizations and deaths. there is still no specific, highly effective treatment for this disease. this study aimed to compare the efficacy of the eight treatment regimens for hospitalized patients with covid-19.materials and methods: this retrospective cohort study was conducted on hospitalized patients with laboratory-confirmed covid-19 by a real-time reverse transcriptase polymerase chain reaction (rt-pcr) of nasopharyngeal samples.results: among all patients hospitalized with covid-19 between march to september 2020, 861 patients were included in the study. this study indicated that treatment protocols included either remdesivir or favipiravir were superior to hydroxychloroquine in reducing the risk of in-hospital mortality of the patients with confirmed covid-19, especially in critical patients defined as those who were icu admitted or under mechanical ventilation (hr, 0.43; 95% ci, 0.23 to 0.82; p=0.011 and hr, 0.45; 95% ci, 0.22 to 0.90; p=0.024, respectively). whereas receiving lopinavir/ritonavir in combination with either hydroxychloroquine plus interferon β and corticosteroids (hr, 1.85; 95% ci, 1.17 to 2.94; p=0.009), hydroxychloroquine plus interferon β (hr, 1.66; 95% ci, 1.01 to 2.74; p=0.046), or interferon β (hr, 1.80; 95% ci, 1.12 to 2.89; p=0.015) was associated with a significant increase in this risk.conclusion: our findings indicate that using remdesivir and favipiravir in combination with interferon β and corticosteroids might be beneficial in hospitalized patients with covid-19, especially critical ones.
کلیدواژه Coronavirus disease 2019 ,Critically ill ,In-hospital mortality ,Treatment regimens
آدرس shahid beheshti university of medical sciences, prevention of cardiovascular disease research center, Iran, shahid beheshti university of medical sciences, school of pharmacy, department of clinical pharmacy, Iran, shahid beheshti university of medical sciences, school of pharmacy, department of clinical pharmacy, Iran, shahid beheshti university of medical sciences, prevention of cardiovascular disease research center, Iran, shahid beheshti university of medical sciences, prevention of cardiovascular disease research center, Iran, shahid beheshti university of medical sciences, school of pharmacy, department of clinical pharmacy, Iran, shahid beheshti university of medical sciences, school of pharmacy, department of clinical pharmacy, Iran, tehran university of medical sciences, iranian center of neurological research, neuroscience institute, students’ scientific research center, Iran. universal scientific education and research network (usern), neuroimmunology research association (nira), Iran, tehran university of medical sciences, students’ scientific research center, Iran. universal scientific education and research network (usern), neuroimmunology research association (nira), Iran, shahid beheshti university of medical sciences, prevention of cardiovascular disease research center, school of pharmacy, department of clinical pharmacy, Iran
 
     
   
Authors
  
 
 

Copyright 2023
Islamic World Science Citation Center
All Rights Reserved